首页> 美国卫生研究院文献>Immunology >Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy
【2h】

Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy

机译:放射治疗后宫颈癌患者外周血中人乳头瘤病毒16 E7特异性T辅助1型应答的增加

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It has been suggested that tumour cell lysis by gamma-radiation induces a tumoral antigen release eliciting an immune response. It is not clear how a specific immune response in cervical cancer patients is developed after radiotherapy. This study is an attempt to investigate the role of the human papillomavirus type 16 (HPV-16) E7-specific T helper response before and after radiotherapy. Lymphocytes were isolated from 32 cervical cancer patients before and after radiotherapy and from 16 healthy women. They were stimulated for 12 hr with autologous HPV-16 E7-pulsed monocyte-derived dendritic cells or directly with HPV-16 E7 synthetic peptides: E751–70, E765–84 and E779–98. The cells were stained for CD4, CD69, intracellular interferon-γ (IFN-γ) and interleukin-4 (IL-4) cytokines and analysed by flow cytometry. A specific CD4+ CD69+ IFN-γ+ immune response against HPV-16 E779–98 peptide was observed in 10 of 14 patients (71·4%) after treatment, compared with 4 of 14 (28·5%) before radiotherapy (P = 0·039); however, this response was not associated with a successful clinical response. Before treatment, 5 of 31 patients showed a HPV-16 E779–98-specific T helper type 2 (Th2) response. Interestingly, this response was significantly associated with a decrease in disease-free survival (P = 0·027). These results suggest that a Th2-type cellular response could be useful as a predictor of recurrence and poor prognosis. An increase of the HPV-specific immune response was observed after radiotherapy; however, it is not enough to control completely the disease after treatment. Our results support that the E7-specific T-cell IFN-γ response in cervical cancer patients, rather than reflecting the host’s capability of controlling tumour growth, might be an indicator for disease severity.
机译:已经提出,通过γ射线裂解肿瘤细胞可引起引起免疫反应的肿瘤抗原释放。尚不清楚放射治疗后宫颈癌患者如何产生特异性免疫反应。这项研究是试图研究放射治疗前后人类乳头瘤病毒16型(HPV-16)E7特异性T辅助反应的作用。从放射治疗前后的32例宫颈癌患者和16例健康的女性中分离出淋巴细胞。用自体HPV-16 E7脉冲单核细胞衍生的树突状细胞或直接用HPV-16 E7合成肽E751–70,E765–84和E779–98刺激它们12小时。对细胞进行CD4,CD69,细胞内干扰素-γ(IFN-γ)和白介素-4(IL-4)细胞因子染色,并通过流式细胞仪进行分析。在14位患者中的10位患者中观察到了针对HPV-16 E779–98肽的特异性CD4 + CD69 + IFN-γ + 免疫反应(71治疗后为·4%),而放疗前为14个中的4个(28·5%)(P = 0·039);但是,这种反应与成功的临床反应无关。治疗前,31例患者中有5例表现出HPV-16 E779–98特异性2型T辅助反应(Th2)。有趣的是,这种反应与无病生存期的减少显着相关(P = 0·027)。这些结果表明,Th2型细胞反应可作为复发和预后不良的预测指标。放疗后,HPV特异性免疫反应增加;然而,仅仅治疗后仅仅控制疾病是不够的。我们的结果支持宫颈癌患者中E7特异性T细胞IFN-γ反应,而不是反映宿主控制肿瘤生长的能力,可能是疾病严重程度的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号